RemSleep Holdings, Inc. is a medical device manufacturer focused on forever changing the level of treatment provided to obstructive sleep apnea patients. On April, 27, 2021 they were granted their utility patent by the USPTO for their sleep apnea nasal pillows device.
This is a monumental achievement for the cpap therapy company founded by highly successful industry veterans who are also listed on over a dozen other patents in the cpap therapy space.
The patent is for the DeltaWave interface, which is designed to provide unparalleled breathability and patient comfort, as patients will be able to easily enjoy normal breathing rates with no mechanical interruption. This will immediately result in better sleep and with fewer side effects.
OSA is largely ignored in the US, as there are roughly 80% of the estimated 29.4 million American cases going undiagnosed each year. This is extremely unfortunate as these comorbidities are associated with increased mortality in OSA patients compared to the general population.
Obstructive sleep apnea (OSA) occurs when one’s throat muscles relax while sleeping, as this leads to the cessation of breathing for extended periods of time. OSA starves vital organs of oxygen, which then causes daytime sleepiness, tiredness, the inability to fully concentrate, and other longer-term comorbidities such as hypertension, obesity, diabetes mellitus, and even cardiac alterations.
To overcome OSA, CPAP machines (continuous positive airway pressure) and interfaces (masks & headgear) were developed to supply a stream of pressurized air to the patient to prevent the collapse of nasal airways and throat muscles during sleep.
But CPAP is far from perfect. In fact, even after 40 years of development, more than 50% of patients who are prescribed them quit using them within 30 days.
The CPAP interface products RemSleep has created take the treatment of obstructive sleep apnea to incredible new heights, and this specifically starts with their revolutionary DeltaWave nasal pillow device. The DeltaWave nasal pillow delivers air to the user in a way that creates a pressure difference that patients don’t even notice, virtually eliminating the “work of breathing” problem.
According to RemSleep, the now patented DeltaWave was strategically built with flow dynamics in mind as it utilizes a nasal-pillows interface that fosters better compliance. This directly addresses a DME Business survey (Durable Medical Equipment suppliers) which revealed that mask-interface breathability and comfort were the primary concern for 89% of patients.
The unique DeltaWave design produces improved air pressure and flow delivering air to the user in a more laminar manner (smoother flow, less turbulence) than traditional CPAP interfaces on the market.
When using the DeltaWave, patients can expect a consistent rate of 14 breaths/minute (which is what your brain signals as normal) rather than the 9 breaths/minute that many other CPAP interfaces in the market traditionally deliver. With DeltaWave, patients will experience no more interrupted sleep and better night time recovery.
RemSleep’s founder’s previous design did roughly $200M in sales, and the team’s experiences on the “work of breathing” component has been lauded for some time in the industry. Now, with the DeltaWave, the next level is approaching.
RemSleep’s R&D advantage has helped them uncover the following two basic tests, which any CPAP interface must pass in order to be truly compliant with treatment:
No other CPAP interface on the market passes both of these tests – but the DeltaWave does! All without interruption to a patient’s normal breathing mechanics including tidal volume (the size of breath), this is where the breakthrough is.
The DeltaWave has been specifically designed with many unique airflow characteristics that enable patients with sleep apnea to breathe normally. For one, it delivers a greater number of air molecules to the nasal entry port, and at a slower air velocity.
Why is this important? Because it allows for increased lateral pressure to the nasal mucosal membranes of the sinus area and a decrease in driving pressure. In addition to this benefit, it will not dry or irritate the sinuses like so many other interfaces on the market do.
Some other product features & benefits that the DeltaWave nasal pillow brings to patients, sleep techs, and physicians include:
- Simple device assembly and use with no formal training needed
- Comfortable, interchangeable silicone inserts that come in multiple sizes
- Neoprene head straps and a swivel connector for seamless mobility
- Designed with improved venting for breathing comfort
- Clears sinuses during use while retaining virtually no CO2
RemSleep’s Outlook for the Future:
- Sales distribution networks pending thanks to the huge success of their founder’s previous design, which did roughly $200M in sales.
- Utility patent secured for the DeltaWave air delivery system.
- Supply chain is up & running, with all manufacturers sourced.
The Size of the Sleep Apnea Market:
The global sleep apnea devices market size was valued at $3.7 billion USD in 2020 and it is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028.
According to an American Sleep Association study published in 2020, an estimated 50 million to 70 million people in the U.S. are suffering from some form of sleep disorders. Moreover, according to Canadian Respiratory Journal in 2014, around 5.4 million adults in Canada were diagnosed with sleep apnea or were at higher risk of developing OSA. According to a study conducted by ResMed in 2018, around 175 million people in Europe were suffering from sleep apnea.
